港股異動 | 中國飛鶴(6186.HK)漲4.5% 機構看高公司股價至20.87港元
格隆匯9月10日丨中國飛鶴(6186.HK)高開後持續走強,現報17.08港元,漲幅4.5%,最新總市值1525.81億。第一上海證券指,截止至2020上半年,公司實現營業收入87.1億人民幣,市佔率達15.2%是中國幼兒奶粉市場第一品牌。目前國產品牌市場份額正在快速回升,預計未來五年內,中國奶粉市場髙端化及本土化將是整個行業發展的主旋律,飛鶴作為國產奶粉領軍者,有望迎來良好的增長機遇。預計公司2020年實現營收收入為186.9億元,歸母淨利潤59.0億元,歸母淨利率為31.6%,未來三年複合增長率有望達到25.6%。給予公司買入評級,目標價20.87港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.